SB 212 creates the “prescription drug cost and affordability review act” and establishes a new prescription drug affordability board within the Kansas insurance department, along with a 21-member stakeholder council to advise it. The board would be appointed by the governor and staffed by members with expertise in health economics, health policy, health equity, and clinical medicine, while the council would include representatives of manufacturers, insurers, employers, pharmacists, physicians, hospitals, managed care organizations, researchers, senior advocates, labor, and the public. The bill also creates a dedicated state fund to pay for the board’s work and requires annual reporting to the legislature, plus a one-time study on generic drug pricing, insurance premiums, cost-sharing, shortages, Medicaid spending, and the effect of upper payment limits on 340B entities.
Beginning in 2027, the board would identify certain high-cost or rapidly increasing prescription drug products for review. The selection criteria include brand-name drugs and biologics with high annual wholesale acquisition costs or large annual price increases, biosimilars that are not sufficiently cheaper than the reference biologic, and generic drugs with high prices and large price spikes. The board may also review other drugs that create affordability challenges, including drugs needed during a public health emergency. After review, the board could adopt rules establishing upper payment limits for selected drugs if it determines the drugs are causing affordability problems or high out-of-pocket costs for patients.
The bill would have a direct effect on how certain prescription drugs are purchased, billed, and reimbursed in Kansas. Once an upper payment limit is set, prescription drug purchasers and third-party payers could not pay or reimburse above that limit, and pharmacies could not be reimbursed below it. The attorney general would be authorized to investigate violations and seek civil relief. The bill also sets procedural rules for appeals, open records treatment with trade-secret protections, and limits the board’s use of certain cost-effectiveness methods, including restrictions on using cost-per-QALY analyses to disadvantage people based on age, disability, or severity of illness.
Because no committee transcripts or recorded votes were provided, the overall sentiment cannot be measured from legislative debate or roll calls. Based on the bill’s structure, it appears designed to address prescription drug affordability and patient cost burdens, suggesting a policy goal of consumer relief and cost containment. At the same time, the bill’s creation of a price-review board and authority to impose upper payment limits indicates a significant regulatory approach that would likely draw scrutiny from manufacturers, pharmacy benefit managers, and other industry stakeholders.
The main points of contention are likely to center on the board’s authority to set upper payment limits, the criteria used to select drugs for review, and the potential impact on market pricing, access, and supply. The bill explicitly includes manufacturers, PBMs, insurers, providers, and patient advocates in the stakeholder council, signaling that competing interests are expected. Additional likely concerns include the treatment of proprietary information, the effect on 340B-covered entities, and whether the board’s cost-effectiveness review standards are too restrictive or too permissive.
SB 212 would add a new regulatory framework to Kansas health insurance and prescription drug policy by creating a state board empowered to review drug pricing and, for selected products, set enforceable upper payment limits. It would affect manufacturers, pharmacies, health insurers, pharmacy benefit managers, third-party payers, and prescription drug purchasers, while expressly excluding Kansas Medicaid and certain managed care organizations from the bill’s definition of third-party payor. The act would also establish a new state fund, require annual reporting and a pre-2027 study, and authorize enforcement through the attorney general and administrative appeals under the Kansas Administrative Procedure Act.
No committee discussion or vote history was provided, so there is no recorded legislative sentiment to summarize from debate or roll call. The bill’s text reflects a strong pro-affordability and consumer-protection orientation, with emphasis on lowering prescription drug costs and limiting patient out-of-pocket expenses. At the same time, the inclusion of industry representatives on the stakeholder council and confidentiality protections for proprietary information suggest an attempt to balance affordability goals with stakeholder concerns.
Likely areas of contention include whether Kansas should create a state board with authority to impose upper payment limits on prescription drugs, how broad the selection criteria should be for drugs subject to review, and whether the board’s cost-effectiveness analysis provisions could affect access for older adults or people with disabilities. Manufacturers and other industry stakeholders may object to price controls and disclosure of pricing information, while patient advocates, senior groups, and healthcare organizations are likely to support efforts to reduce drug costs. The bill also raises potential disputes over impacts on 340B entities, pharmacy reimbursement, and the extent of state oversight over drug pricing and benefit design.